Journal Club: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Description

Listen to a new Journal Club with PI Dr. Brian Slomovitz and moderator Dr. Leslie Randall as they discuss details on the New England Journal of Medicine published article Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

Click here to read The New England Journal of Medicine article

Click here to listen to podcast

Presented by:

Brian Slomovitz
Director of Gynecologic Oncology
Co-Chair, Cancer Research Committee
Mount Sinani Medical Center
USA

Moderated by:

Leslie Randall
Director of Gynecologic Oncology Clinical Research and Gynecologic Cancer Service Line
Inova Schar Cancer Institute
Inova Health System
USA

Supported in part by

Summary

Availability:

On-Demand

Cost:

FREE

Create Account

Recommended

Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications

FREE

Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer

FREE

IGCS 2024 Cervical Master Sessions: Moving Forwards

FREE

Radical Hysterectomy - Surgical Film Festival

$0.00 - $50.00

Journal Club: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

FREE

Redefining Platinum Sensitivity : Additional Treatment Considerations in a Changing Paradigm

FREE

Patient reported outcomes exploring quality of life in PROC and novel therapeutics: mirvetuximab in recurrent ovarian cancer

FREE

Journal Club:Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE)

FREE

IGCS 2024 Endometrial Cancer Master Session

FREE

Uterine Cancers in the Molecular Era: Changing Trends and Implications

FREE